论文部分内容阅读
目的客观评价降纤酶治疗急性脑梗死患者血浆纤维蛋白原动态变化。方法将 60例急性脑梗死患者随机分为治疗组和安慰剂组。用药方案为隔日静脉给药 3次 ,降纤酶的首次剂量为 10 U,第 2、3次为 5 U,在发病 2 4小时内开始治疗。对照组用同样方式给予安慰剂。用药前及用药后第 2、3、5、7天检测血浆纤维蛋白原水平。结果治疗组用药后血浆纤维蛋白原有明显下降 ,与安慰剂组比较有显著性差异 (P<0 .0 5 ) ,尤其用药后第 2、3天差异更为明显 (P<0 .0 1)。结论研究表明降纤酶是降解血浆纤维蛋白原安全、有效的药物
Objective To objectively evaluate the dynamic changes of plasma fibrinogen in patients with acute cerebral infarction treated with defibrase. Methods Sixty patients with acute cerebral infarction were randomly divided into treatment group and placebo group. The drug regimen was given intravenously three times a day, the first dose of defibrase was 10 U, the second and third were 5 U, and treatment started within 24 hours of onset. The control group received placebo in the same manner. Plasma fibrinogen levels were measured before treatment and on days 2, 3, 5 and 7 after treatment. Results After treatment, the plasma fibrinogen of the treatment group decreased significantly compared with the placebo group (P <0.05), especially after the 2nd and 3rd days, the difference was more significant (P0.01 ). Conclusion Studies have shown that defibrase is a safe and effective drug for degrading plasma fibrinogen